ライフサイエンスコーパス: galectin

1 ranging from 3 to 20 mg/ml depending on the galectin).

2 new function for receptor glycosylation and galectins.

3 ases, displayed propensity to associate with Galectins.

4 carbohydrate recognition among tandem-repeat galectins.

5 s for a family of multivalent lectins called galectins.

6 h physiological concentrations of a panel of galectins.

7 hort, which revealed that increased lymphoma galectin-1 (Gal-1) expression strongly correlated with r

8 It was recently described that Galectin-1 (Gal-1) promotes axonal growth after spinal c

9 fabricated for the quantitative detection of Galectin-1 (Gal-1) protein, a biomarker for the onset of

10 Galectin-1 (Gal-1), a glycan-binding protein with broad

11 Galectin-1 (Gal-1), a member of a family of evolutionari

12 Here we show that galectin-1 (Gal-1), an endogenous lectin that recognizes

13 In this article, we show that galectin-1 (Gal-1), an immunoregulatory lectin widely ex

14 We demonstrate that galectin-1 and -3 are expressed by the human cervical an

15 ozoan derivatives to dissect the function of galectin-1 and -3 in the context of Trichomonas infectio

16 The homodimeric adhesion/growth-regulatory galectin-1 and a set of covalently linked homo-oligomers

17 mmunosuppressive microenvironment, including galectin-1 and PD-L1/2.

18 This study thus identifies Galectin-1 as a master regulator of clinically relevant

19 Glycan-dependent Galectin-1 binding induced a set of disease markers, inc

20 s had no surface galectin-3 but used surface galectin-1 for interaction with Gal-3BP to form large ol

21 mphatic endothelial cells, and deposition of galectin-1 in extracellular matrix selectively regulates

22 Silencing galectin-1 increased and adding exogenous galectin-1 sup

23 Here, we show that galectin-1 is also highly expressed by human lymphatic e

24 is, galectins, we tested the hypothesis that Galectin-1 is relevant for causing degeneration.

25 In order to exhibit an enhancing effect, galectin-1 must be present during the initial phase of v

26 f virus attachment; in contrast, addition of galectin-1 postinfection results in reduced production o

27 lectin galectin-3; galectin-3 siRNA but not galectin-1 siRNA prevented MUC1-induced upregulation of

28 ity to galectin-3 but maintained affinity to galectin-1 suppressed chemokine expression.

29 ng galectin-1 increased and adding exogenous galectin-1 suppressed chemokine responses to Trichomonas

30 Galectin-1 suppressed chemokines that facilitate recruit

31 ial cells express the innate immune effector galectin-1 that we have previously shown can bind to spe

32 unohistochemical analysis substantiated that Galectin-1 upregulation is associated with osteoarthriti

33 polypeptide, apolipoproteins A-Ib and A-II, galectin-1, and vitellogenin-6 during degeneration when

34 Galectin-3 and galectin-1, binding partners of LGALS3BP, potentiate mon

35 eficient cells displayed enhanced binding to galectin-1, indicating that changes in GNE activity can

36 hibitors led to dose-dependent impairment of Galectin-1-mediated transcriptional activation.

37 osis similar to that of a known nonselective galectin-1/galectin-3 inhibitor, which strongly suggests

38 confirmed the found abundance differences in galectin 10 and protein S100-A9 between the groups.

39 Moreover, recombinant galectin-10 by itself was able to suppress T cell prolif

40 Moreover, we show that galectin-10 functions as a T cell-suppressive molecule i

41 children with EoE also had higher levels of galectin-10 mRNA and lower levels of FOXP3 mRNA.

42 Eosinophil FOXP3 and galectin-10 mRNA levels were determined by qPCR.

43 We found that Ab-mediated neutralization of galectin-10 partially abrogated the suppressive function

44 Finally, we detected galectin-10-containing immune synapses between eosinophi

45 evels of CD23, CD44, CD54, CRTH2, FOXP3, and galectin-10.

46 ntain stores of the immunoregulatory protein galectin-10.

47 luble form of ST2 (33 [24.6-48.1] ng/mL) and galectin 3 (17.8 [14.1-22.8] ng/mL) were higher, and for

48 33 ng/mL soluble form of ST2 and <17.8 ng/mL galectin 3) had reduction in left atrial volume, those a

49 by baseline level of soluble form of ST2 and galectin 3; patients with values less than the observed

50 Colocalization of alphaS pathology with galectin-3 (a marker of endo-lysosomal membrane rupture)

51 Galectin-3 (Gal-3) can cross-link surface glycoproteins

52 ing were used to investigate the function of galectin-3 (Gal-3) during the process of leukocyte recru

53 Galectin-3 (Gal-3) has been linked to cardiac remodeling

54 Galectin-3 (Gal-3) is a carbohydrate binding lectin, wit

55 Mammalian beta-galactoside-binding protein Galectin-3 (Gal-3) modulates the host innate and adaptiv

56 nflammation markers soluble (s)CD163, sCD14, galectin-3 (Gal-3), and Gal-3 binding protein (Gal-3BP)

57 hree different endocytic ligands-folic acid, galectin-3 (Gal3) and the Shiga toxin B-subunit (STxB).

58 We studied the role of galectin-3 (Gal3) in gastric infection by Helicobacter p

59 Galectin-3 (Gal3), a lectin mainly secreted by macrophag

60 Galectin-3 (Gal3), a pleiotropic lectin, is produced by

61 ng protein (gal3bp) and its receptor/ligand, galectin-3 (gal3), are secreted proteins that initiate s

62 In further studies, we focused on galectin-3 (Gal3), identified in this study as a negativ

63 Using two different galectin-3 affinity purification processes, we extracted

64 onic anhydrase-12, and NC markers brachyury, galectin-3 and CD24 in cells of the NP irrespective of a

65 Galectin-3 and galectin-1, binding partners of LGALS3BP,

66 in promoting MUC16's binding affinity toward galectin-3 and in causing retention of the lectin on the

67 The impact of galectin-3 and protease expression on S. aureus virulenc

68 us approximately 10S particle that contained galectin-3 and U1 snRNP and this particle was sufficient

69 nti-fibronectin antibody and beta-lactose, a galectin-3 antagonist, significantly blocked DC exosome-

70 ions 3-5) of the glycerol gradient with anti-galectin-3 antibodies.

71 The role of galectin-3 as a modulator of inflammation has been studi

72 These findings suggest LGALS3BP and galectin-3 as new targets to treat metastatic cancer and

73 the self-association-related multivalency of galectin-3 at the residue-specific level.

74 rn blot, an intact ( approximately 28.0 kDa) galectin-3 band was identified in tear samples from heal

75 Purification indicated that Galectin-3 binding protein (LGALS3BP) is the active fact

76 Moreover, galectin-3 bound to N-linked glycans on CD146 and induce

77 chomonas CPI-GC that had reduced affinity to galectin-3 but maintained affinity to galectin-1 suppres

78 uctures; the MDA-MB-231 cells had no surface galectin-3 but used surface galectin-1 for interaction w

79 lectin-3 inhibition, showed no inhibition of galectin-3 by the polysaccharides.

80 d phase separation, and we demonstrated that galectin-3 can also undergo liquid-liquid phase separati

81 We report that galectin-3 can bind to TLR-4, and that administration of

82 In addition, galectin-3 colocalized predominantly with the HPS-5 comp

83 In conclusion, galectin-3 concentrations increased with progressive ren

84 Mean+/-SD galectin-3 concentrations were 12.8+/-4.0 ng/ml (eGFR>/=

85 nt interactions of transmembrane mucins with galectin-3 contribute to maintenance of the epithelial b

86 istration of a neutralizing antibody against galectin-3 decreases the expression of IL-1beta, IL-6, T

87 ns and clinical isolates of S. aureus caused galectin-3 degradation.

88 Taking all together, galectin-3 emerges as a clinically relevant target for T

89 artilage surface, and addition of multimeric galectin-3 enhances cartilage lubrication.

90 tion of galectin-3 protein in tears, but not galectin-3 expression in conjunctival epithelium, was si

91 use model of transverse aortic constriction, galectin-3 expression was markedly up-regulated in the p

92 leomorphism, fibrous septation and increased galectin-3 expression, consistent with atypical parathyr

93 vity troponin I (hsTnI), soluble (s)ST2, and galectin-3 from baseline to 26, 52, and 104 weeks.

94 ed with the ability of active MMP9 to cleave galectin-3 from recombinant origin.

95 bitor, which strongly suggests that blocking galectin-3 glycan recognition is an important antifibrot

96 Galectin-3 has an intrinsically disordered N-terminal do

97 Galectin-3 has been implicated in a broad range of biolo

98 Galectin-3 has been linked to incident renal disease, ex

99 We also find that galectin-3 has low affinity for the surface layer of ost

100 In contrast, parallel anti-galectin-3 immunoprecipitation of free galectin-3 molecu

101 One specific TRIM, TRIM16, interacted with Galectin-3 in a ULK1-dependent manner.

102 e show a large increase in the expression of galectin-3 in microglia and also an increase in the rele

103 We investigated the role of galectin-3 in systemic and local responses in a murine m

104 The cooperation between TRIM16 and Galectin-3 in targeting and activation of selective auto

105 and also an increase in the released form of galectin-3 in the cerebrospinal fluid (CSF) 24 h after h

106 mes detected the presence of fibronectin and galectin-3 in those derived from DCs, whereas T-cell exo

107 sing cell-based assays, indirectly linked to galectin-3 inhibition, showed no inhibition of galectin-

108 r to that of a known nonselective galectin-1/galectin-3 inhibitor, which strongly suggests that block

109 sulted in highly selective and high affinity galectin-3 inhibitors.

110 ur results indicate that release of cellular galectin-3 into tears is associated with epithelial dysf

111 for these proteases and that proteolysis of galectin-3 is a novel immune evasion mechanism.

112 These data indicate that galectin-3 is a regulatory component in melanin synthesi

113 bers present in synovial fluid, we find that galectin-3 is a specific, high-affinity binding partner

114 We find that galectin-3 is broadly up-regulated in KLF3-deficient mou

115 how expression of the inflammatory modulator galectin-3 is controlled, opening up avenues for potenti

116 The galactoside-binding protein galectin-3 is increasingly recognized as an important pl

117 enabling multivalency for various functions, galectin-3 is monomeric, and its functional multivalency

118 ts potential role as a prognostic biomarker, galectin-3 is not a critical modulator of cardiac fibros

119 The beta-galactoside-binding animal lectin galectin-3 is predominantly expressed by activated macro

120 The beta-galactoside-binding protein galectin-3 is widely expressed in well-differentiated th

121 europrotection in the cortical region in the galectin-3 knockout animals in response to TBI.

122 Galectin-3 knockout mice exhibited accelerated cardiac h

123 7 days of pressure overload, whereas female galectin-3 knockouts had delayed dilation after 28 days

124 t cardiomyocyte- but not macrophage-specific galectin-3 localization was associated with adverse remo

125 However, galectin-3 loss did not affect survival, systolic and di

126 We propose that galectin-3 may achieve multivalency through this multisi

127 suggest that following head trauma, released galectin-3 may act as an alarmin, binding, among other p

128 We hypothesized that galectin-3 may be up-regulated in the pressure-overloade

129 hat CD146/MCAM interactions with circulating galectin-3 may have an important influence on cancer pro

130 Serum galectin-3 modestly increased from baseline with canagli

131 anti-galectin-3 immunoprecipitation of free galectin-3 molecules not in a complex with U1 snRNP (fra

132 inding ligand and strongly co-localized with galectin-3 on endothelial cell surfaces treated with exo

133 ex and that U1 snRNP is required to assemble galectin-3 onto an active spliceosome.

134 ds its cognate elements (CACCC boxes) in the galectin-3 promoter and represses its activation in cell

135 Remarkably, galectin-3 promotes cellular infiltration in the heart o

136 The concentration of galectin-3 protein in tears, but not galectin-3 expressi

137 epithelial dysfunction in dry eye, and that galectin-3 proteolytic cleavage may contribute to impair

138 In contrast, silencing galectin-3 reduced IL-8 response to LPG.

139 Galectin-3 regulates inflammasome activation in cholesta

140 Galectin-3 regulates inflammatory and fibrotic responses

141 Together, our results suggest that galectin-3 reinforces the lubricin boundary layer; which

142 ats (VNTRs) that bind the lectin galectin-3; galectin-3 siRNA but not galectin-1 siRNA prevented MUC1

143 In vitro, cytokine stimulation suppressed galectin-3 synthesis by macrophages and cardiac fibrobla

144 of antibody showed much higher affinity for galectin-3 than that of the commercial antibody.

145 Considering the known ability of galectin-3 to crosslink glycoproteins, we hypothesized t

146 rects cytosolic carbohydrate-binding protein Galectin-3 to PVs and that the delivery of GBP1 and GBP2

147 ppel-like factor 3 (KLF3) directly represses galectin-3 transcription.

148 In normal mouse myocardium, galectin-3 was constitutively expressed in macrophages a

149 Galectin-3 was increased in TSC-related skin tumors, ang

150 Signature component Lgals3 encoding galectin-3 was increased in Tsc2-deficient cells and ser

151 Early up-regulation of galectin-3 was localized in subpopulations of macrophage

152 is partly attributable to the interaction of galectin-3 with unknown receptor(s) on vascular endothel

153 iguingly, YopK limited the colocalization of Galectin-3 with YopD, suggesting that YopK limits the in

154 overall showed smaller lesion sizes than the galectin-3(+/+) animals.

155 In galectin-3(+/+) mice, SspB-expressing S. aureus caused l

156 tic liver injury, we generated dnTGF-betaRII/galectin-3(-/-) (dn/Gal3(-/-)) mice, which showed impair

157 acterial load or lesion size was detected in galectin-3(-/-) mice, which overall showed smaller lesio

158 5 (growth differentiation factor 15), GAL-3 (galectin-3), and Cys-C (cystatin-C) were assessed before

159 erminal pro-B-type natriuretic peptide], and galectin-3).

160 We hypothesized that human galectin-3, a beta-galactoside-binding lectin involved i

161 the staphylococcal protease SspB inactivates galectin-3, abrogating its stimulation of oxygen radical

162 lso observed colocalization between YopD and Galectin-3, an indicator of endosomal membrane damage.

163 ammation and caused up-regulation of Cxcl16, Galectin-3, and Nedd9, among others.

164 brogated by bacterium-derived proteolysis of galectin-3, and SspB was identified as the major proteas

165 This correspondence is a reply to Galectin-3, Cardiac Function, and Fibrosis by Wouter C.

166 Despite considerable interest in galectin-3, little is known about its physiological regu

167 2 (an interleukin-1 receptor family member), galectin-3, matrix metalloproteinase-2, and collagen III

168 tumorgenicity 2, highly sensitive troponin, galectin-3, midregional proadrenomedullin, cystatin-C, i

169 However, the association among galectin-3, renal function, and adverse outcomes has not

170 rms a lattice with the N-glycan of TRPV5 via galectin-3, which impairs TRPV5 endocytosis and increase

171 We have shown previously that circulating galectin-3, which is increased up to 30-fold in cancer p

172 We demonstrate that melanocytes express galectin-3, which is predominantly localized to the cell

173 The method employs a (89)Zr-labeled mAb to galectin-3, which shows high specificity and binding aff

174 CD146 was the major galectin-3-binding ligand and strongly co-localized with

175 Thus, CD146/MCAM is the functional galectin-3-binding ligand on endothelial cell surfaces r

176 Here we sought to identify the galectin-3-binding molecule(s) on the endothelial cell s

177 Galectin-3-binding protein (gal3bp) and its receptor/lig

178 roteinase 9, S100A8/S100A9, cathepsin D, and galectin-3-binding protein) improved risk prediction and

179 00A8), S100A9, cathepsin B, fibronectin, and galectin-3-binding protein.

180 uoles or YCVs is substantially diminished in Galectin-3-deficient cells.

181 of the impaired immune response observed in galectin-3-deficient mice in vivo.

182 cretion systems into PV membranes stimulates Galectin-3-dependent recruitment of antimicrobial GBPs t

183 ates but not in Staphylococcus saprophyticus Galectin-3-induced activation of the neutrophil NADPH ox

184 of CD146 expression completely abolished the galectin-3-induced secretion of IL-6 and G-CSF cytokines

185 on endothelial cell surfaces responsible for galectin-3-induced secretion of metastasis-promoting cyt

186 endothelial cell surface responsible for the galectin-3-mediated cytokine secretion.

187 w document that this interaction between the galectin-3-U1 snRNP particle and the pre-mRNA results in

188 depleted extract can be reconstituted by the galectin-3-U1 snRNP particle, isolated by immunoprecipit

189 These results indicate that the galectin-3-U1 snRNP-pre-mRNA ternary complex is a functi

190 in fibrotic areas contained large amounts of galectin-3.

191 NKp30 blocking Ab and an inhibitory ligand, galectin-3.

192 functional beta-galactoside-binding protein, galectin-3.

193 homonas depleted the extracellular levels of galectin-3.

194 ors become upregulated, including the lectin galectin-3.

195 thelial cell surfaces treated with exogenous galectin-3.

196 tandem repeats (VNTRs) that bind the lectin galectin-3; galectin-3 siRNA but not galectin-1 siRNA pr

197 ancer xenografts that express high levels of galectin-4 along with genetic signatures of EGFR-HER2 si

198 Our findings establish galectin-4 and C1GALT1-mediated glycosylation in a signa

199 Parallel changes in galectin-4 and O-glycosylation triggered aberrant recept

200 Galectin-4 binding to multiple receptor tyrosine kinases

201 In vivo investigations established that galectin-4 expression enabled prostate cancer cells to r

202 Galectin-4 expression in clinical specimens of prostate

203 Galectin-4 is a tandem-repeat galectin characterized by

204 Notably, these effects of galectin-4 relied upon O-glycosylation mediated by C1GAL

205 Here, we investigate galectin-4 using X-ray crystallography, small- and wide-

206 In particular, human galectin-4, normally expressed in the healthy gastrointe

207 the first time a structural model for human galectin-4.

208 Finally, we establish that galectin-7 can be associated with JNK1 and protect it fr

209 Increased galectin-7 expression upregulates c-Jun N-terminal kinas

210 Rescue of miR-203 expression in a galectin-7 knockdown model reduces p63 expression to bas

211 Here, we demonstrate that galectin-7 knockdown results in reduced differentiation

212 A knockdown of either galectin-7 or miR-203 in keratinocytes increases express

213 and deep-sequencing analyses, we found that galectin-7 positively and negatively regulates microRNA

214 We show that galectin-7 regulates keratinocyte differentiation and pr

215 Galectin-7, a member of the beta-galactoside-binding pro

216 ur data suggest an intracellular function of galectin-7: regulation of keratinocyte proliferation and

217 The sensor of this mechanism, galectin-8 (encoded by LGALS8), detects permeated endoso

218 Alteration of the linker length in human galectin-8 and single-site mutation (F19Y) are used here

219 argo receptors, and "eat-me" signals such as galectin-8 and ubiquitin that label bacteria as autophag

220 We also found that the danger receptor galectin-8 detects damaged endomembranes and activates a

221 PAR and MRC2) and negatively (LRP1) regulate galectin-8 function.

222 ted in inflamed human and mouse corneas, and galectin-8 inhibitors reduce inflammatory lymphangiogene

223 Galectin-8 is markedly upregulated in inflamed human and

224 osteoblasts can be attributed to binding of galectin-8 to receptor complexes that positively (uPAR a

225 lectins, namely, surfactant protein D, human galectin-8, and Siglec-14, to different NTHi clinical is

226 nstrate that a carbohydrate-binding protein, galectin-8, promotes pathological lymphangiogenesis.

227 Inhibition of galectin-8- and NDP52-dependent autophagy increased seed

228 ns alpha1beta1 and alpha5beta1 curtails both galectin-8- and VEGF-C-mediated LEC sprouting.

229 ular mechanism of lymphangiogenesis in which galectin-8-dependent crosstalk among VEGF-C, podoplanin

230 model of corneal allogeneic transplantation, galectin-8-induced lymphangiogenesis is associated with

231 he Lgals8(-/-) and Pdpn(-/-) mice; likewise, galectin-8-induced lymphangiogenesis is reduced in Pdpn(

232 tingly, knockdown of VEGFR-3 does not affect galectin-8-mediated lymphatic endothelial cell (LEC) spr

233 Secretion of RANKL by galectin-8-treated osteoblasts can be attributed to bind

234 Upon disruption of the dectin 1-galectin 9 axis, CD4(+) and CD8(+) T cells, which are di

235 We found that dectin 1 can ligate the lectin galectin 9 in mouse and human PDA, which results in tole

236 Galectin-9 (Gal-9) is highly expressed in the liver and

237 cell immunoglobulin and mucin domain (TIM-3)-Galectin-9 (Gal-9) signaling regulates CD4+ Th1 immune r

238 so can bind to the tandem repeat-type lectin galectin-9 (Gal-9), and signaling through mouse (m)4-1BB

239 gnaling through mouse (m)4-1BB is reduced in galectin-9 (Gal-9)-deficient mice, suggesting a pivotal

240 The patients with high Galectin-9 expression in recurrent NPC frequently also h

241 CD4, Foxp3 and Tim-3 in lymphocytes, and of Galectin-9 in tumour cells between paired primary and re

242 as significant increase in the expression of Galectin-9+ tumour cells (p < 0.001) and Foxp3+ lymphocy

243 patients (60%) had increased percentages of Galectin-9+ tumour cells and of Foxp3+ lymphocytes, resp

244 c advantage than primary NPC, especially the Galectin-9/Tim-3 pathway.

245 The immunotherapies targeting Galectin-9/Tim-3/Foxp3 interaction may serve as a potent

246 Galectins, a family of glycan-binding proteins widely ex

247 th Plasmodium berghei ANKA (PbANKA) to block galectins and found significantly elevated total protein

248 ffinity interaction, but the multivalency of galectins and the glycan ligands presented on cell surfa

249 TRIM16, through integration of Galectin- and ubiquitin-based processes, coordinated rec

250 Galectins are a family of lectins that bind beta-galacto

251 Galectins are a family of mammalian carbohydrate-binding

252 Some galectins are made by immune cells, whereas other galect

253 Galectins are proteins involved in diverse cellular cont

254 tins are made by immune cells, whereas other galectins are secreted by different cell types, such as

255 Glycan-binding proteins, which include galectins, are involved at all stages of immunity and in

256 Our findings identify galectins as new players in osteoclastogenesis and bone

257 e to interaction of the polysaccharides with galectins because the polysaccharides contain galactose-

258 Galectins bind N-acetyllactosamine (LacNAc) units within

259 new poly-LacNAc extension by B3GNT maintains galectin binding and immune homeostasis.

260 s) expressed by that cell, and the effect of galectin binding results from clustering or retention of

261 We find that competitive inhibition of galectin binding results in lubricin loss from the carti

262 Galectin binding to a single glycan ligand is a low-affi

263 Galectin binding to a specific glycoprotein counterrecep

264 richomoniasis and warrant further studies of galectin-binding diversity among clinical isolates as a

265 inding, Trichomonas is capable of regulating galectin bioavailability and function to the benefit of

266 Galectins can function intracellularly and can also be s

267 s are not due to inhibition of the canonical galectin carbohydrate-binding site.

268 , inducible nitric oxide synthase, annexins, galectin, cathepsins and heat shock proteins), whereas t

269 Galectin-4 is a tandem-repeat galectin characterized by two carbohydrate recognition d

270 tin knockdown epithelial clones, recombinant galectins, clinical Trichomonas isolates, and mutant pro

271 e of Davanat(R), had an inhibitory effect of galectins comparable with that of free galactose.

272 mportantly, the hybrid vesicles bind a human galectin, consistent with the display of sugar moieties

273 rosslink glycoproteins, we hypothesized that galectins could augment lubrication via biomechanical st

274 ing the molecular and cellular components of galectin-driven regulatory circuits, the implications of

275 selective roles of individual members of the galectin family in cancer-promoting inflammation, immuno

276 Of the galectin family members present in synovial fluid, we fi

277 n such processes between the TRIM family and Galectin family of proteins.

278 infection, here we investigated the roles of galectin (Gal)-1, 3, 8, 9 and the receptors of Gal-9 (Ti

279 Galectin (Gal)-3 is a beta-galactoside-binding lectin an

280 nerate bioequivalent N-glycans that preserve galectin-glycoprotein interactions and cellular homeosta

281 narily conserved galactoside-binding site of galectins has not been demonstrated.

282 haracterization of full-length tandem-repeat galectins has remained elusive.

283 saccharide, was screened against three human galectin (hGal) proteins (a stable mutant of hGal1 (hGal

284 T signaling in patient cells, whereas adding galectins impaired these processes in control cells.

285 Unlike the other 14 known galectins in mammalian cells, which have dimeric or tand

286 We used an in vitro model with siRNA galectin knockdown epithelial clones, recombinant galect

287 finity of cell-surface glycoproteins for the galectin lattice.

288 ctures with N-acetyllactosamine, a preferred galectin ligand.

289 titis virus, a beta-CoV in group A, uses the galectin-like NTD in its spike protein to bind its recep

290 and this particle was sufficient to load the galectin polypeptide onto a pre-mRNA substrate.

291 milk oligosaccharides (HMOs) for four human galectin proteins, a stable mutant of hGal1 (hGal-1), a

292 The binding data show that each of the four galectins recognize the majority of the HMOs tested (hGa

293 Removing IFN-gammaR2 T168N-bound galectins restored lateral diffusion in lipid nanodomain

294 guration in pectins had no inhibition of the galectins tested.

295 How do galectins translate glycan-containing information into c

296 adhesion/growth-regulatory lectins, that is, galectins, we tested the hypothesis that Galectin-1 is r

297 lycan, together with artificially engineered galectins, were used to understand the physiological sig

298 regulated by the interaction of cell surface galectins with branched N-glycans.

299 Twenty-five of the HMOs tested bind all four galectins, with affinities ranging from 10(3) to 10(5) M

300 ical galactoside-binding site for the tested galectins, with IC50 values >10 mg/ml for a few or in mo